BR112014004504A2 - "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" - Google Patents

"composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"

Info

Publication number
BR112014004504A2
BR112014004504A2 BR112014004504A BR112014004504A BR112014004504A2 BR 112014004504 A2 BR112014004504 A2 BR 112014004504A2 BR 112014004504 A BR112014004504 A BR 112014004504A BR 112014004504 A BR112014004504 A BR 112014004504A BR 112014004504 A2 BR112014004504 A2 BR 112014004504A2
Authority
BR
Brazil
Prior art keywords
kit
medicament
compound
treatment
compounds
Prior art date
Application number
BR112014004504A
Other languages
English (en)
Other versions
BR112014004504B1 (pt
Inventor
Nguyen Bao
Michael James Petrassi Hank
Loren Jon
Nabakka Juliet
Molteni Valentina
Yeh Vince
Liu Xiaodong
Li Xiaolin
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BR112014004504A2 publication Critical patent/BR112014004504A2/pt
Publication of BR112014004504B1 publication Critical patent/BR112014004504B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Abstract

resumo patente de invenção: "compostos e composições como inibidores de c-kit cinase". a presente invenção refere-se a compostos de fórmula (i) e (ii) e a composições farmacêuticas dos mesmos, que são úteis como inibidores de proteína cinase, bem como métodos para uso de tais compostos para tratar, melhorar ou prevenir uma condição associada com atividade cinase anormal ou desregulada. em algumas modalidades, a invenção fornece métodos para uso de compostos para tratar, melhorar ou impeder doenças ou distúrbios que envolvem a ativação anormal de c-kit ou c-kit e pdgfr (pdgfr?, pdgfr?) cinases.
BR112014004504-6A 2011-09-01 2012-08-28 Inibidor de c-kit cinase, seu uso, e composição farmacêutica BR112014004504B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
US61/530,028 2011-09-01
PCT/US2012/052621 WO2013033070A1 (en) 2011-09-01 2012-08-28 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
BR112014004504A2 true BR112014004504A2 (pt) 2017-03-28
BR112014004504B1 BR112014004504B1 (pt) 2022-03-22

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004504-6A BR112014004504B1 (pt) 2011-09-01 2012-08-28 Inibidor de c-kit cinase, seu uso, e composição farmacêutica

Country Status (41)

Country Link
US (1) US9199981B2 (pt)
EP (1) EP2751102B1 (pt)
JP (1) JP6117208B2 (pt)
KR (1) KR101959590B1 (pt)
CN (1) CN103764653B (pt)
AP (1) AP2014007494A0 (pt)
AR (1) AR087752A1 (pt)
AU (1) AU2012300248B2 (pt)
BR (1) BR112014004504B1 (pt)
CA (1) CA2845159C (pt)
CL (1) CL2014000494A1 (pt)
CO (1) CO6900140A2 (pt)
CR (1) CR20140106A (pt)
CU (1) CU20140023A7 (pt)
CY (1) CY1121695T1 (pt)
DK (1) DK2751102T3 (pt)
EA (1) EA024293B1 (pt)
ES (1) ES2732671T3 (pt)
GT (1) GT201400036A (pt)
HR (1) HRP20191140T1 (pt)
HU (1) HUE044373T2 (pt)
IL (1) IL231226A (pt)
JO (1) JOP20120246B1 (pt)
LT (1) LT2751102T (pt)
MA (1) MA35459B1 (pt)
ME (1) ME03395B (pt)
MX (1) MX342329B (pt)
MY (1) MY167245A (pt)
PE (1) PE20141033A1 (pt)
PL (1) PL2751102T3 (pt)
PT (1) PT2751102T (pt)
RS (1) RS59025B1 (pt)
SG (1) SG2014011050A (pt)
SI (1) SI2751102T1 (pt)
TN (1) TN2014000061A1 (pt)
TR (1) TR201909189T4 (pt)
TW (1) TWI543981B (pt)
UA (1) UA110841C2 (pt)
UY (1) UY34300A (pt)
WO (1) WO2013033070A1 (pt)
ZA (1) ZA201401113B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
CN109568319A (zh) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
JP2016539166A (ja) * 2013-12-05 2016-12-15 バイエル・ファルマ・アクティエンゲゼルシャフト アリール−およびヘテロアリール置換イミダゾ[1,2−a]ピリジン−3−カルボキサミドおよびその使用
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
MA42293A (fr) 2015-07-02 2018-05-09 Janssen Sciences Ireland Uc Composés antibactériens
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
CA3025727A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
CA3026010A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
US10231966B2 (en) 2016-10-27 2019-03-19 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
EA201991997A1 (ru) 2017-03-01 2020-01-22 Янссен Сайенсиз Айрлэнд Анлимитед Компани Комбинированная терапия
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022533340A (ja) * 2019-05-13 2022-07-22 ノバルティス アーゲー N-(5-(5-((1R,2S)-2-フルオロシクロプロピル)-1,2,4-オキサジアゾール-3-イル)-2-メチルフェニル)イミダゾ[1,2-a]ピリジン-3-カルボキサミドの結晶形態
WO2021048342A1 (en) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022011483A (es) 2020-03-17 2022-10-07 Sumitomo Pharma Co Ltd Derivado de oxadiazol.
JP2023534963A (ja) * 2020-07-15 2023-08-15 サード ハーモニック バイオ, インコーポレイテッド 選択的c-kitキナーゼ阻害剤の結晶質形態
US20220175740A1 (en) * 2020-11-19 2022-06-09 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性c-kit激酶抑制劑之醫藥組合物及其製造及使用方法
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
EP4308239A1 (en) 2021-03-16 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2024509997A (ja) 2021-03-17 2024-03-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌化合物
EP4308579A1 (en) 2021-03-17 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
RU2009120882A (ru) 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы
CN103313968A (zh) * 2010-11-15 2013-09-18 Abbvie公司 Nampt和rock抑制剂
EP2751105A1 (en) * 2011-09-01 2014-07-09 Irm Llc Compounds and compositions as c-kit kinase inhibitors
CA2845785A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013033167A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors

Also Published As

Publication number Publication date
IL231226A0 (en) 2014-04-30
AR087752A1 (es) 2014-04-16
ES2732671T3 (es) 2019-11-25
PE20141033A1 (es) 2014-08-30
EP2751102B1 (en) 2019-03-27
PL2751102T3 (pl) 2019-09-30
LT2751102T (lt) 2019-07-10
MX342329B (es) 2016-09-26
TR201909189T4 (tr) 2019-07-22
IL231226A (en) 2017-03-30
ME03395B (me) 2020-01-20
AU2012300248B2 (en) 2015-08-27
KR20140071382A (ko) 2014-06-11
TN2014000061A1 (en) 2015-07-01
CA2845159A1 (en) 2013-03-07
PT2751102T (pt) 2019-07-10
UY34300A (es) 2013-04-05
US20130059846A1 (en) 2013-03-07
KR101959590B1 (ko) 2019-03-18
DK2751102T3 (da) 2019-07-01
WO2013033070A1 (en) 2013-03-07
CR20140106A (es) 2014-05-02
AP2014007494A0 (en) 2014-03-31
ZA201401113B (en) 2015-10-28
MA35459B1 (fr) 2014-09-01
SG2014011050A (en) 2014-08-28
CL2014000494A1 (es) 2014-09-05
CN103764653A (zh) 2014-04-30
EP2751102A1 (en) 2014-07-09
TWI543981B (zh) 2016-08-01
JP2014525444A (ja) 2014-09-29
UA110841C2 (uk) 2016-02-25
EA024293B1 (ru) 2016-09-30
HUE044373T2 (hu) 2019-10-28
BR112014004504B1 (pt) 2022-03-22
JOP20120246B1 (ar) 2022-03-14
SI2751102T1 (sl) 2019-08-30
CY1121695T1 (el) 2020-07-31
US9199981B2 (en) 2015-12-01
NZ621092A (en) 2016-06-24
MX2014002482A (es) 2014-11-25
EA201490540A1 (ru) 2014-06-30
MY167245A (en) 2018-08-14
GT201400036A (es) 2015-06-02
TW201313716A (zh) 2013-04-01
CN103764653B (zh) 2015-12-02
CO6900140A2 (es) 2014-03-20
JP6117208B2 (ja) 2017-04-19
AU2012300248A1 (en) 2014-04-17
HRP20191140T1 (hr) 2019-09-20
RS59025B1 (sr) 2019-08-30
CA2845159C (en) 2020-11-03
CU20140023A7 (es) 2014-04-24

Similar Documents

Publication Publication Date Title
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
EA201000341A1 (ru) 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
BR112013026202A2 (pt) composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014026703A2 (pt) inibidores de dna-pk
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
BR112015002118A2 (pt) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2012, OBSERVADAS AS CONDICOES LEGAIS.